Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

Core Viewpoint - Geron Corporation is set to release its fourth quarter and full year 2025 financial results on February 25, 2026, and will host a conference call to discuss these results [1][2]. Company Overview - Geron Corporation is a commercial-stage biopharmaceutical company focused on changing the course of blood cancer [3]. - The company's first-in-class telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and the European Union for treating certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) who have transfusion-dependent anemia [3]. - Geron is conducting a pivotal Phase 3 clinical trial of imetelstat in patients with JAK-inhibitor resistant/refractory myelofibrosis (R/R MF) and is also exploring its use in other hematologic malignancies [3]. - The mechanism of action involves inhibiting telomerase activity, which is elevated in malignant stem and progenitor cells in the bone marrow, potentially reducing proliferation and inducing death of malignant cells [3].